Incannex Healthcare Reports Decrease in Operating Losses and Increase in Cash Reserves

Incannex Healthcare Inc. reported its financial results for the three and nine months ended March 31, 2026, revealing a significant increase in cash reserves and a reduction in operating losses compared to the previous fiscal period. The company recorded a net loss of $3.9 million for the three months ended March 31, 2026, a slight decrease from the $4.0 million loss reported in the same period of the previous year. For the nine-month period, the net loss was $16.8 million, compared to $15.3 million for the nine months ended March 31, 2025. The company did not generate any revenue during the current quarter, maintaining the same status as the previous year.

The financial performance of Incannex showed notable changes, particularly in operating expenses. Total operating expenses decreased to $4.0 million for the three months ended March 31, 2026, down from $5.0 million in the prior year, primarily due to a reduction in research and development (R&D) expenses, which fell by 88% to $321,000. For the nine-month period, total operating expenses increased slightly to $17.8 million from $16.3 million, driven by higher general and administrative costs, which rose by 52% to $14.1 million. The increase in general and administrative expenses was attributed to higher stock-based compensation and consulting fees.

Strategically, Incannex has made significant moves, including a reverse stock split executed on February 26, 2026, at a ratio of 1-for-30, aimed at increasing the per-share price of its common stock. Additionally, the company completed a registered direct offering on March 12, 2026, raising approximately $10 million through the sale of shares and warrants. This capital infusion is expected to support ongoing clinical trials and operational expenses. The company continues to focus on its lead drug candidates, including IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder, both of which are in various stages of clinical development.

Operationally, Incannex reported a cash and cash equivalents balance of $74.5 million as of March 31, 2026, a significant increase from $15.0 million at the end of the previous fiscal year. This increase is attributed to successful financing activities, including the recent offering. The company’s current assets exceeded its current liabilities by $78.2 million, indicating a strong liquidity position. However, the company continues to face challenges in generating revenue, as it has not yet commercialized any of its drug candidates.

Looking ahead, Incannex anticipates that its cash reserves will be sufficient to fund operations for at least the next twelve months. The company plans to continue its focus on advancing its clinical programs while exploring additional financing options to support its growth. Despite the ongoing losses, management remains optimistic about the potential for future revenue generation once its drug candidates receive regulatory approval and enter the market.